Spero Therapeutics Receives $30,000,000 Series A Funding

  • Feed Type
  • Date
    6/8/2015
  • Company Name
    Spero Therapeutics
  • Mailing Address
    400 Technology Square 10th Floor Cambridge, MA 20139 USA
  • Company Description
    Spero Therapeutics’ vision is to find, develop, and advance groundbreaking therapeutics to meet critical patient needs in infectious disease using a unique business and drug discovery model. Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections.
  • Website
    http://www.sperotherapeutics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $30,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Spero plans to use the proceeds from this financing to advance the Potentiator franchise into clinical development by 2016, progress its anti-virulence program in partnership with Roche through the submission of an Investigational New Drug (IND) application, and develop additional programs in its pipeline focused on unmet medical needs in bacterial infections.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy